July 29 (Reuters) - Medical device maker Boston Scientific on Wednesday lowered its annual profit forecast, citing pressure on its Watchman heart device business.
The company, in May, warned of pressure on its Watchman heart device, a small implant used to help prevent stroke-causing blood clots in patients with atrial fibrillation, due to softer-than-expected uptake.
Boston Scientific said growth was being weighed down by a decline in standalone Watchman procedures as physicians increasingly combine the implant with other cardiac treatments during a single visit.
As a result, the company said it expects flat Watchman revenue growth in the second and likely third quarter, despite continued uptake in combined procedures.
On Monday, Boston Scientific's board approved a new company-wide restructuring plan aimed at cutting costs and better positioning the company for future growth.
#uptake
The company, in May, warned of pressure on its Watchman heart device, a small implant used to help prevent stroke-causing blood clots in patients with atrial fibrillation, due to softer-than-expected uptake.
Boston Scientific said growth was being weighed down by a decline in standalone Watchman procedures as physicians increasingly combine the implant with other cardiac treatments during a single visit.
As a result, the company said it expects flat Watchman revenue growth in the second and likely third quarter, despite continued uptake in combined procedures.
On Monday, Boston Scientific's board approved a new company-wide restructuring plan aimed at cutting costs and better positioning the company for future growth.
#uptake
3 months ago
